In consultation: Guidance and quality standards
Showing 1 to 10 of 28
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID6437 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Norucholic acid for treating primary sclerosing cholangitis [ID6583] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Bepirovirsen for treating chronic hepatitis B ID6608 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232] | Draft guidance | Technology appraisal guidance | |
| Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489] | Draft guidance | Technology appraisal guidance | |
| Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA ID6540 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Elamipretide for treating Barth syndrome in people of any age [ID6545] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487] | Draft guidance | Technology appraisal guidance | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Draft guidance | Technology appraisal guidance |